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The gap in the commercially-available pediatric drug products and formulations suitable for children, especially
those below the age of 6 years, is long recognized. A group of clinicians and scientists with a common interest in
pediatric drug development and medicines-use systems developed a practical framework for identifying a list of
active pharmaceutical ingredients (APIs) with the greatest market potential for development to use in pediatric
patients. Reliable and reproducible evidence-based drug formulations designed for use in pediatric patients are
needed vitally, otherwise safe and consistent clinical practices and outcomes assessments will continue to be
difficult to ascertain. Identification of a prioritized list of candidate APIs for oral formulation using the described
algorithm provides a broader integrated clinical, scientific, regulatory, and market basis to allow for more reliable
dosage forms and safer, effective medicines use in children of all ages. Group members derived a list of candidate
API molecules by factoring in a number of pharmacotherapeutic, scientific, manufacturing, and regulatory variables
into the selection algorithm that were absent in other rubrics. These additions will assist in identifying and
categorizing prime API candidates suitable for oral formulation development. Moreover, the developed algorithm
aids in prioritizing useful APIs with finished oral liquid dosage forms available either adapted from other countries
or the aim to register them in North America and beyond.Background
Childhood illnesses often require the use of medications
under the premise of “off-label” use. In February 2014,
the American Academy of Pediatrics (AAP) released a
policy statement from its Committee on Drugs regarding
the off-label use of drugs (medications) in children
(Committee on Drugs 2014). For the purpose of the
statement the Committee defined “off-label” use as “that
use which is not included in the package insert (Food
and Drug Administration (FDA)-approved labeling) for
that drug and is “neither experimentation nor research”
(Committee on Drugs 2014). Such off-label use of drugs* Correspondence: rxvarsha@gmail.com
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the Creative Commons license, and indicate ifin children does not require any oversight by any institu-
tional (Investigational Review Board) or federal regula-
tory agency. Use of drugs without appropriate research
in children can put this population at significant risk for
adverse events. Off-label use combined with use of
medication management systems designed for adults
and adapted for use in children can compound the risk
of adverse events due to increased potential for medica-
tion errors. We have addressed the issue of medication
management systems in a Special Issue of Pharmacy
Paediatrics, published recently in the online journal,
Pharmacy, at mdpi.com (Parrish & Cernak 2015). Here,
we make an attempt to identify other issues related to
off-label use of drugs, and present a systematic approach
to selection of API candidate molecules amenable to a
novel formulation methodology suitable for children.is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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problem?
The issue of off-label use of drugs in neonates, infants
and children has prevailed for many decades. Federal
legislation to address this issue was first proposed in
1998 and reauthorized in 2012. Since that time, various
government agencies including FDA and the National
Institute of Child Health and Human Development
(NICHD) have worked together to develop pediatric-
inclusive product labeling for existing and new drug
molecules coming to the market, if the drug has been or
could be used in children. The European Medicines
Agency (EMA) also adopted a similar legislation in 2007.
According to a recent study published in JAMA-
Pediatrics, the US legislation has produced 406 pediatric
labeling changes; out of those, only 24 labels include
data on neonatal drug dosing (Laughon et al. 2014). The
EMA regulation found the number of pediatric investi-
gation plans increased for new molecular entities, but it
also identified neonates as the least studied population
after the new legislation was introduced (Better Medicines
for Children: From Concept to Reality 2013). Identified
factors for lack of appropriate drug dosing data in children
go beyond the efforts of the FDA and NICHD, which
formed partnership almost two decades ago to address this
issue and formed collaborations with academia and a
number of other entities to enhance this knowledge. Some
have also called into question the ethics of non-beneficial
pediatric research, that is, what is good clinical practice
on permissible risk in incompetent (pediatric) patients?
(Piasecki et al. 2015) Current dosing regimens of most
drugs used in neonates, infants and children are de-
rived from extrapolation of adult data rather than from
systematic pharmacokinetic (PK)/pharmacodynamics (PD)
study of drugs in these populations. A major barrier to
generation of appropriate dosing regimens based on sound
PK/PD data is lack of uniform drug formulation. Many
dosage forms of drugs used in these populations today in
institutions in US and in the world are extemporaneously
compounded and lack validated product uniformity.
Often, clinical trials protocols include products prepared
using non-standard compounding methods at the site of
the investigation. These formulation factors can result in
significant variability in drug disposition studies since it is
often unclear whether the variation originates from the
patient or the product. Thus, translational research in
pediatrics is not only necessary for new drug moieties, but
also for approved pharmaceuticals used frequently without
regard to dosage forms and formulation properties, both
of which could significantly affect their bioavailability,
plasma concentrations and therapeutic effect.
In practice, children less than 12 years of age are gener-
ally not able or prefer not to swallow tablets or capsules,
thus frequently requiring a liquid dosage form, or a solubleor chewable preparation. Unfortunately, there is a distinct
lack of such formulations on the market which leads to
extemporaneous compounding as the only practicable reso-
lution (Nahata & Allen 2008). There are many reasons for
this market deficiency including formulation difficulties and
identification of suitable existing and new APIs amenable
to liquid/soluble formulations. The diversity of the pediatric
population (age range, physical size and swallowing capabil-
ities) which varies significantly from birth to 12 years of
age, along with the variability in dosing based on size, age,
weight etc. produces many challenges in pediatric formula-
tion development mostly associated with the difficulty in
defining design of the intended dosage form that is most
appropriate for the target patient population.
Traditionally, to enhance the solubility of poorly soluble
compounds by conventional formulation approaches in
most cases, drug formulation is developed with an aim to
create a supersaturated solution when it comes into con-
tact with an aqueous environment. This often requires use
of solubilizing agents and precipitation inhibitors. Some of
the other popular formulations approaches for achieving
this solubilization are the lipid-based formulations called
self-emulsifying and self-micro emulsifying drug delivery
systems. These systems enhance solubility and hence oral
bioavailability of lipophilic drugs, presenting the drug in
solubilized form in vivo. This phenomenon avoids dissol-
ution, which can be the rate limiting step in drug absorp-
tion for sparingly soluble drugs. It also avoids addition of
solubilizing agents or precipitation inhibitors reducing
excipient exposures. Some other technologies used to
improve drug solubility and bioavailability includes the
production of high energy or rapid dissolving solid state
formulations using drug particle engineering. Examples of
such formulations include solid dispersions, nanoparticles,
and co-ground mixtures (Charkoftaki et al. 2012).
In recent years, there has been an increased effort to
develop solid pediatric formulations that deliver the ap-
propriate dose in a “user friendly” way and to find alter-
native drug delivery vehicles, such as mini-tablets as well
as new taste masking techniques in order to improve
drug acceptability in children. Solid state formulations
such as mini tabs have a limitation in that they still lack
the dosing accuracy needed for dosing the very young
patient less than 1 year of age where liquid formulations
are preferred for ease of administration as well as accur-
acy of dosing since dosing in this group of patients is
generally weight based and often results in fractional
dosing. This leads to continual need for extemporaneous
compounding for this patient population.
In the following sections, we present a rubric that
incorporates clinical and market-oriented variables in
relation to existing APIs commonly used in pediatric
practice that lack mass-produced formulations suitable
for younger patients less than 6 years of age, despite
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years for pediatric population friendly formulations de-
scribed above. The purpose of this rubric is to easily
identify such molecules and explore the possibility of
production of physically and chemically stab le formu-
lations with a long shelf life that can be made available
for easy use as well as help alleviate or minimize
extemporaneous compounding. We overlay an array of
scientific factors that support the selection of these
APIs for mass-production, including Biopharmaceutical
Classification System (BCS) and propose hot-melt ex-
trusion (HME) process, a technology that has received
significant attention in recent years, as a potentially
flexible liquid formulation production technique for low
solubility APIs suitable for a wide range of pediatric
patients including premature neonates.
Development of the algorithm for a tiered
selection model for candidate APIs
Between September and December 2013, a North-American
group of pharmacists, pediatricians, and pharmaceutical
scientists formed Meds4Kids Research Collaborative, LTD
(M4KRC). This group of clinicians and scientists with
a common interest in pediatric drug development and
medicines-use systems developed a framework for
developing drugs in dosage forms suitable for use in
pediatric patients (Fig. 1). The group met in a series
of six conference calls to determine a list of candidateFig. 1 M4KRC framework for collaborative pediatric drug developmentAPI molecules that possessed the greatest clinical, sci-
entific, and market potential for mass production.
The proposed criteria for determining potential candi-
date API molecules were prioritized primarily based
on Best Pharmaceuticals for Children Act (BPCA),
which lists broad-based clinical developmental needs
within pediatrics. Below is the first phase rubric that
the group selected for the API molecules:
1. Listed on BPCA priority document (clinical need –
broad base);
2. Available in an injection (compound is stable in
solution for at least 18–24 months);
3. Not a federally controlled substance in Canada or
the US (minimal paperwork for chain of custody);
4. Potential applicability for oral adult market (for
patients that cannot swallow tablets or capsules);
5. Established indication for any age group in the
official labeling of the compound (immediate
marketability through accelerated mechanisms) and
6. Off-patent in both Canada and the US, and available
in a pharmaceutical grade powder from a reputable
supplier.
The group reviewed the BPCA list and compared it to
the list of 50 compounded non-sterile products (CNPs)
prepared extemporaneously at St. Christopher’s Hospital
for Children, all of which had scientific evidence for
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non-sterile product list 2013 St. Christopher's Hospital
for Children, unpublished). The clinicians (VBM, RHP,
and JJC) adjudicated the list using a scoring system that
assigned a score for each API molecule’s potential from
a pharmacotherapy perspective. In the third meeting, a
seventh factor was incorporated into the algorithm; the
availability of a mass-produced oral liquid dosage form in
the United Kingdom. Then, in the last two meetings, the
scientists (RBM and RL) integrated the clinician-derived
list with the biopharmaceutical properties that com-
plemented and validated the clinical rankings for the
identified APIs.
The original list was then segmented into four tiers:
 The first tier included API molecules that met at
least five of the six criteria;
 The second tier fulfilled four criteria;
 The third tier included API molecules not listed by
name in the BPCA list but met all other criteria
except availability in the United Kingdom; and
 The fourth tier included those available in the UK
that could be imported readily for pharmacokinetic
(PK), pharmacodynamics (PD), and/or
pharmacogenomics (PG) studies in children.
Several API molecules were removed from the list
because of new market entry (enalapril), availability of
one oral liquid strength (levetiracetam), known physi-
cochemical problems (acetylsalicylic acid), or low use
potential in children (pravastatin). The final, fourth tier
API molecules, identified based on criteria of potential
viability as candidates ready for PK/PD/PG studies, are
listed in Table 1.
Effective drug delivery and viable mass
manufacturing – applying BCS and HME to
candidate APIs
The next step for the group was to apply scientific prin-
ciples of drug delivery and formulation techniques to the
clinically-derived list that would enhance the likelihood
of the commercial availability of a mass-producedTable 1 M4KRC fourth tier candidate API molecules
Generic name BCPA listed? Injection? Non-scheduled? Oral adult m
Baclofen 1 1 1 1
Warfarin 1 1 1 1
Sildenafil 1 1 1 1
L-thyroxine 1 1-lyo 1 1
aAvailable as 5 mg/mL oral solution at http://medicines.org.uk/emc/medicine/14939
bAvailable as 1 mg/mL oral suspension at http://medicines.org.uk/emc/medicine/23
cAvailable as 10 mg/mL suspension powder at http://medicines.org.uk/emc/medicin
dAvailable as 5 microgram/mL and 20 microgram/mL at http://medicines.org.uk/emproduct. Effective delivery and viable manufacturing are
essential to improve the clinical and commercial value of
a pharmaceutical product. A reliable formulation will
not only ensure optimal clinical outcomes, but also
assure reproducibility in manufacturing, increased stabil-
ity and longer shelf life making the product economically
viable. The gap in the commercially available pediatric
drug products and dosage forms, which is long recog-
nized, is currently bridged daily primarily by the efforts
of compounding pharmacists, especially in the hospital
setting. APIs are routinely compounded extemporan-
eously from adult solid oral dosage forms into liquid
forms to provide medications that otherwise are not
available to vulnerable pediatric populations, such as
children with cardiovascular disease, cancer, cystic fibro-
sis, organ transplants, and other life threatening and rare
diseases.
It has been noted that these compounding practices,
despite best efforts and intentions, do not incorporate the
necessary manufacturing controls to assure reproducible
product potency, stability, and purity. Formal efforts to as-
sist pharmacists and other practitioners to compound the
best products possible include methods and guidelines
found in the United States Pharmacopeia, FDA regula-
tions and guidance documents, professional working
groups, and elsewhere (Compounding Compendium).
Working groups focusing on the topic date back to at least
1977, when the American Society of Hospital Pharmacists
Special Interest Group on Pediatric Pharmacy Practice
started working on the issue. This group continues to
meet to the current day (Jew et al. 2010).
When compared to Good Manufacturing Practices
(GMPs), the manufacturing standards required by FDA
for commercial products, there are multiple recognized
deficiencies inherent in extemporaneous formulation-
compounding suitable for pediatric patients, which
include the following:
 Lack of specifications required for component
development by compounding pharmacies.
 No onsite testing of active ingredients and excipients
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containers and closures.
 Site-to-site variations in compounding procedures,
equipment, and the degree of preparation handling/
manipulation.
 Lack of environmental control, which might lead to
unintentional contamination and generation of
degradation products due to inconsistent exposure
to light, temperature and processing controls.
 Lack of testing of finished preparations for purity,
potency, content or stability.
 Stability data for establishing expiry dates of
compounded products are derived from published
data, where preparation methods likely vary from
local methods, or are simply default expiry periods
defined by regional pharmacy regulations and
“best practices” or applicable USP Chapters 795,
797 and 1191.
 Published preparation methods provide only a
portion of the information needed to consistently
prepare a stable potent final compounded preparations.
 Limited options available to mask bad-tasting active
ingredients.
 The dose administration technologies used such as
droppers, syringes, scoops, spoons, etc., vary
between sites and between prescription fills.
 Weak regulatory oversight.
Unfortunately, there are a number of barriers to the
development of pediatric drug formulations under
GMPs, not the least of which are economic in nature
(Vanchieri et al. 2008). The first barrier concerns the
market size. The elderly population (65 years of age and
older) spends, on average, about 10 times more than the
pediatric population (0–17 years of age) on medications.
With regard to production, development of a unique
pediatric formulation can take up to two years or more,
with a cost ranging from $8 million to $15 million
(Milne 2011). The second barrier relates to the need
for incorporating taste-masking methods suitable for
children; and the third is due to the need to develop
dosage forms such as liquids, suspensions, small tablets,
films and chewable tablets that can be easily administered
to children.
The Biopharmaceutical Drug Classification System
(BCS) was introduced by Amidon et al. in 1995 (Amidon
et al. 1995). Today, this classification system is accepted
by most regulatory agencies like the US FDA, Health
Canada and European Medicines Agency (EMA). APIs
are classified into one of four quadrants according to
their potential bioavailability (Löbenberg & Amidon 2000).
Solubility and permeability are the two parameters used for
the classification. Only if a drug can dissolve in the gastro-
intestinal tract can it be absorbed, and only if it is absorbedit can have a systemic effect. BCS class I drugs have high
solubility and high permeability; class II are poorly soluble
but highly permeable; class III are highly soluble but poorly
permeable and class IV are poorly soluble and poorly
permeable. Wu and Benet linked metabolism to the
BCS classification, and showed that class I and II drugs
can be highly metabolized and be subject to transporters,
while class III and IV drugs are poorly metabolized or
transported (Wu & Benet 2005). If two pharmaceutically
equivalent finished drug products with BCS class 1&3
have similar dissolution behavior at pH 1.2, 4.5 and 6.8,
then they can be considered therapeutically equivalent
and bioequivalence has been demonstrated through
in vitro methods (Löbenberg et al. 2012) as outlined in the
WHO, EMA and Health Canada Biowaiver guidelines
(WHO Expert Committee on Specifications for Pharma-
ceutical Preparations 2006; EMA 2010; Health Canada
2014). FDA currently only grants biowaivers for BCS class
1 APIs (U.S. Department of Health and Human Services
Food and Drug Administration Center for Drug Evalu-
ation and Research (CDER) 2000) but might update its
guidance in the future to include BCS class three drugs
(U.S. Department of Health and Human Services Food
and Drug Administration Center for Drug Evaluation and
Research (CDER) 2025).
This approach can be used in the development of
pediatric dosage forms if an identical strength already
exists. The knowledge of the BCS class helps pharma-
ceutical companies in drug development. For example, a
class I drug might need much less formulation work
compared to a class II drug where solubility must be im-
proved (Almukainzi et al. 2014). The BCS classes of
APIs with the highest potential for pediatric formulation
development are listed in Table 2, and could be applied
to all WHO-listed essential medicines for children
(Takagi et al. 2006; Ramirez et al. 2010; Fiftieth Report
of the WHO Expert Committee on Specifications for
Pharmaceutical Preparations 2016; Dahan et al. 2013).
One of the manufacturing methods that can address
many of the solubility problems of BCS class 2 and 4 drugs
is the hot-melt extrusion (HME) technology (Maniruzza-
man et al. 2012). HME disperses the active ingredient(s) as
a matrix at the molecular level, thus forming solid solutions
without the use of excessive heat or solvents while preserv-
ing drug potency. The HME approach has been successful
in improving the delivery and human absorption of
poorly water-soluble compounds. Extruded solid solu-
tions (i.e. the end product of HME) offer greater
thermodynamic stability compared to products pre-
pared by alternative processes such as spray drying,
solvent evaporation and other hot melt methods.
Concerning economics, HME can be used to produce
small (on a GMP scale) lots of a formulated product.
The final production sizes of these small lot sizes,
Table 2 BCS class and potential candidate molecules for
pediatric drug development

















Uncl. unclassified, n.d. no data
aProvisional BCS Classification. http://www.tsrlinc.net/results.cfm
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velopment batches or Clinical Trial Manufacturing
(CTM) batches, are within the range of 10,000 to 50,000
units. The flexibility to produce small batches using
HME process may provide a sufficient commercial mar-
ket for a given pediatric population for a year or more.
Compared to commercial tableting or capsule manufac-
turing approaches, which incorporate processes such as
milling, mixing, spray drying, wet granulation, pre-
compression, compression, tableting/encapsulation,
HME is a much more economical process with re-
duced production time, fewer processing steps, and is
suitable for continuous operation (Abdel-Rahman et al.
2012; Batchelor et al. 2014).
With regards to formulation attributes and taste mask-
ing, HME can produce final drug products with sustained,
modified, and targeted release properties, and can also
coat poor tasting products. So, the finished product can
then be milled in a single step to form powders suitable
for incorporation into child-friendly dosage forms such as
mini-tablets, orally disintegrating tabs, and liquid suspen-
sions. The output of the extrusion process, known as an
extrudate, can be optimized to protect the API against
changing pH conditions, light, heat, and moisture levels,
thus confer good stability properties to the final formu-
lation. While characterization of the pediatric gut
awaits a more complete description, HME provides a
useful tool for poorly soluble, highly permeable APIs
(Batchelor & European Paediatric FormulationInitiative (EUPFI) 2014; Tannergren et al. 2009; Flynn
et al. 2014; Crowley et al. 2007).
An example of an API suitable for HME process is
metoprolol succinate. Metoprolol is one of the most
commonly used beta-blocking agents used in children
from infancy through adolescence and into adulthood to
treat a variety of cardiovascular conditions as an antihy-
pertensive and heart rate modulator (Repka et al. 2007).
Metoprolol succinate is a freely soluble compound ac-
cording to the Martindale (Sweetman SC). Metoprolol is
often used as borderline drug to differentiate between
high and low permeability drugs (Löbenberg & Amidon
2000). The required average pediatric dose ranges from
5 to 50 mg/day. Hence, a minimum concentration of
about 2.5 mg/mL, with a maximum concentration of
10 mg/mL is desired.
Metoprolol is an excellent example of an HME candi-
date. HME process can increase the dissolution rate of the
drug for deriving clinically acceptable concentrations with
ease of reconstitution for a given strength. The process
will also deliver good content uniformity of the drug and
minimize risk for segregation. Overall, the manufacturing
process is very simple, and involves only blending and
processing using tight process controls. The HME process
allows for in-process monitoring of the product quality
using process analytical tools (e.g. Near Infra-Red (NIR)
Spectroscopy). Moreover, there is no need for scaling up
and down for different batch sizes. As with many com-
mercial pediatric formulations currently in use (especially
for existing molecules) as well as extemporaneously com-
pounded formulations that still await PK/PD data, the PK/
PD of formulations produced using HME technology
would also need to be studied.
In summary, the M4KRC-derived list of candidate API
molecules has been derived from selection matrix that
factored in a number of pharmacotherapeutic, bio-
pharmaceutical, scientific, manufacturing, and regulatory
variables absent in other rubrics. These additions guided
the group to identify the prime API candidates suitable
for children in mass produced dosage forms. Further,
the market-focused algorithm helped to prioritize useful
APIs, and to facilitate clinical studies with finished oral
liquid dosage forms available from other countries with
direct importation potential to North America. BCS lass
II molecules are best suited for formulation using HME
technologies. However, as seen with metoprolol other
factors might also need to be considered. Incorporating
BCS classification into the final selection of candidate
APIs, the following molecules are suggested for formula-
tion and development: metoprolol, clopidogrel, spironolac-
tone, and nifedipine. The assessment of these other
variables, in addition to clinical and market parameters, is
very important to increase the likelihood that a pharma-
ceutical manufacturer would successfully mass-produce
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(Public Assessment Report for paediatric studies submitted
in accordance with Article 45 of Regulation (EC) No1901/
2006 & as amended. Metoprolol succinate 2013; Allen &
Erickson 1996).
Conclusion
Successful public private partnerships have moved the sci-
ence of pediatric clinical pharmacology forward. However,
without reliable and reproducible evidence-based drug
formulations designed for use in a range of pediatric pa-
tients, safe and consistent clinical practices and outcomes
assessments will continue to be difficult to ascertain and
the ethics of such research, marginally justifiable. Identifi-
cation of prime candidate APIs for oral formulation
through incorporation and assessment of production-
related variables will provide a broader integrated clinical,
scientific, regulatory, and market basis, allowing for more
reliable dosage forms for safe and effective medicines use
in children of all ages.
The M4KRC group members derived a list of candidate
API molecules by factoring in a number of these pharma-
cotherapeutic, biopharmaceutical, scientific, manufactur-
ing, and regulatory variables into the selection algorithm
that were absent in other rubrics. These additions have
assisted in identifying and categorizing prime API candi-
dates suitable for oral formulation development. Finally,
the developed algorithm aids in prioritizing useful APIs
with finished oral liquid dosage forms available from other
countries with direct importation opportunities to North
America and beyond. These standardized oral dosage
forms await further clinical testing.
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